The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Case of Malignant Mesothelioma of the Peritoneum and Pleura

복막과 흉막에 발생한 악성 중피종 1예

  • Lee, Su Jin (Department of Internal Medicine, Good Samsun Hospital) ;
  • Park, Mi Jung (Department of Internal Medicine, Good Samsun Hospital) ;
  • Kim, Ok Geun (Department of Internal Medicine, Good Samsun Hospital) ;
  • Jang, Ji Geon (Department of Internal Medicine, Good Samsun Hospital) ;
  • Noh, Ju Ho (Department of Internal Medicine, Good Samsun Hospital) ;
  • Park, Byoung Hwan (Department of Internal Medicine, Good Samsun Hospital) ;
  • Lee, Jin Sook (Department of Pathology, Good Samsun Hospital)
  • Received : 2014.02.13
  • Accepted : 2014.04.07
  • Published : 2014.12.01
⟨ Previous Next ⟩

Abstract

Malignant mesothelioma is a rare aggressive tumor and arises from mesothelial cells in the pleural, peritoneal and pericardial cavities. Median survival is -1 year and the incidence is approximately 0.7 per million persons, and is increasing annually in Korea. It is difficult to diagnose malignant mesothelioma because of nonspecific symptoms, signs and laboratory findings. It needs to be confirmed by histological examination and immunohistochemistry. There is no case report of malignant mesothelioma of the peritoneum and pleura in Korea. We report a rare case of malignant mesothelioma with simultaneous involvement of the peritoneum and pleura in a 75-year-old man without evidence of asbestos exposure.

저자들은 석면 노출력이 없는 75세 남자 환자에서 복막과 흉막에 동시 발생한 악성 중피종의 첫 증례를 경험하여 참고 문헌과 함께 보고하는 바이다.

Keywords

References

  1. An HS, Choi IJ, Han MS, Cha MS. Two cases of malignant mesothelioma of the peritoneum and pericardium. Korean J Obstet Gynecol 2009;52:1331-1337.
  2. Kim HR, Ahn YS, Jung SH. Epidemiologic characteristics of malignant mesothelioma in Korea. J Korean Med Assoc 2009;52:449-455. https://doi.org/10.5124/jkma.2009.52.5.449
  3. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-481. https://doi.org/10.1038/modpathol.3800067
  4. Reck M, Stahel RA, von Pawel J, et al. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. Respir Med 2010;104:142-148. https://doi.org/10.1016/j.rmed.2009.07.019
  5. Kim KU, Kim JE, Jo WS, et al. Three cases of malignant pleural mesothelioma misdiagnosed as tuberculous pleurisy. Tuberc Respir Dis 2007;62:323-330. https://doi.org/10.4046/trd.2007.62.4.323
  6. Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg 2009;1:38-48.
  7. Kim S, Shin YS, Seo YS, Park YS, Nam SL, Seo KS. A case of diffuse malignant mesothelioma of the peritoneum. Korean J Obstet Gynecol 1998;41:2241-2245.
  8. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma‒an update on treatment. Cancer Treat Rev 2012;38:605-612. https://doi.org/10.1016/j.ctrv.2011.10.006
  9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644. https://doi.org/10.1200/JCO.2003.11.136
  10. Fasola G, Puglisi F, Follador A, Aita M, Di Terlizzi S, Belvedere O. Dramatic tumour response to pemetrexed single- agent in an elderly patient with malignant peritoneal mesothelioma: a case report. BMC Cancer 2006;6:289-293. https://doi.org/10.1186/1471-2407-6-289